These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
242 related articles for article (PubMed ID: 6160908)
1. Effect of N-(phosphonacetyl)-L-aspartate on 5-azacytidine metabolism in P388 and L1210 cells. Grant S; Rauscher F; Jakubowski A; Cadman E Cancer Res; 1981 Feb; 41(2):410-8. PubMed ID: 6160908 [TBL] [Abstract][Full Text] [Related]
2. Kinetics of N-(phosphonacetyl)-L-aspartate and pyrazofurin depletion of pyrimidine ribonucleotide and deoxyribonucleotide pools and their relationship to nucleic acid synthesis in intact and permeabilized cells. Moyer JD; Smith PA; Levy EJ; Handschumacher RE Cancer Res; 1982 Nov; 42(11):4525-31. PubMed ID: 7127293 [TBL] [Abstract][Full Text] [Related]
3. N-(phosphonacetyl)-L-aspartate synergistically enhances the cytotoxicity of 5-fluorouracil/interferon-alpha-2a against human colon cancer cell lines. Wadler S; Mao X; Bajaj R; Hallam S; Schwartz EL Mol Pharmacol; 1993 Nov; 44(5):1070-6. PubMed ID: 8246910 [TBL] [Abstract][Full Text] [Related]
4. Collateral sensitivity to N-(phosphonacetyl)-L-aspartic acid in a line of P388 leukemia cells selected for resistance to L-(alpha S, 5S)-alpha-amino-3- chloro-4,5-dihydro-5-isoxazoleacetic acid (acivicin). Ardalan B; Jayaram HN; Johnson RK Cancer Res; 1983 Apr; 43(4):1598-601. PubMed ID: 6831405 [TBL] [Abstract][Full Text] [Related]
5. Mechanism of synergy between N-phosphonacetyl-L-aspartate and dipyridamole in a human ovarian carcinoma cell line. Chan TC; Howell SB Cancer Res; 1985 Aug; 45(8):3598-604. PubMed ID: 4016741 [TBL] [Abstract][Full Text] [Related]
6. Inhibition of cell growth by N-(phosphonacetyl)-L-aspartate in human and murine cells in vitro. Leyva A; Appel H; Smith P; Lankelma J; Pinedo HM Cancer Lett; 1981 Mar; 12(1-2):169-73. PubMed ID: 7273001 [TBL] [Abstract][Full Text] [Related]
7. Flux through the de novo pyrimidine pathway in vivo. Effect of N-phosphonacetyl-L-aspartate, a potent inhibitor of aspartate transcarbamylase. Monks A; Anderson LW; Strong J; Cysyk RL J Biol Chem; 1983 Nov; 258(22):13564-9. PubMed ID: 6417130 [TBL] [Abstract][Full Text] [Related]
8. Differential effect of N-(phosphonacetyl)-L-aspartate on 1-beta-D-arabinofuranosylcytosine metabolism and cytotoxicity in human leukemia and normal bone marrow progenitors. Grant S; Rauscher F; Cadman E Cancer Res; 1982 Oct; 42(10):4007-13. PubMed ID: 6955007 [TBL] [Abstract][Full Text] [Related]
9. Altered 5-azacytidine metabolism following 3-deazauridine treatment of L5178Y and human myeloblasts. Grant S; Cadman E Cancer Res; 1980 Nov; 40(11):4000-6. PubMed ID: 6162541 [TBL] [Abstract][Full Text] [Related]
10. PALA enhancement of bromodeoxyuridine incorporation into DNA increases radiation cytotoxicity to human ovarian adenocarcinoma cells. Yang JL; Fernandes DJ; Wheeler KT; Capizzi RL Int J Radiat Oncol Biol Phys; 1996 Mar; 34(5):1073-9. PubMed ID: 8600090 [TBL] [Abstract][Full Text] [Related]
11. Mechanism of resistance of variants of the Lewis lung carcinoma to N-(phosphonacetyl)-L-aspartic acid. Kensler TW; Mutter G; Hankerson JG; Reck LJ; Harley C; Han N; Ardalan B; Cysyk RL; Johnson RK; Jayaram HN; Cooney DA Cancer Res; 1981 Mar; 41(3):894-904. PubMed ID: 7459875 [TBL] [Abstract][Full Text] [Related]
12. Modulation of metabolism and cytotoxicity of cytosine arabinoside with N-(phosphon)-acetyl-L-aspartate in human leukemic blast cells and cell lines. Noordhuis P; Kazemier KM; Kasperrs GJ; Peters GJ Leuk Res; 1996 Feb; 20(2):127-34. PubMed ID: 8628011 [TBL] [Abstract][Full Text] [Related]
13. Pharmacological and biochemical interactions of N-(phosphonacetyl)-L-aspartate and 5-fluorouracil in beagles. Miller AA; Moore EC; Hurlbert RB; Benvenuto JA; Loo TL Cancer Res; 1983 Jun; 43(6):2565-70. PubMed ID: 6189583 [TBL] [Abstract][Full Text] [Related]
14. Effect of uridine on response of 5-azacytidine-resistant human leukemic cells to inhibitors of de novo pyrimidine synthesis. Grant S; Bhalla K; Gleyzer M Cancer Res; 1984 Dec; 44(12 Pt 1):5505-10. PubMed ID: 6208998 [TBL] [Abstract][Full Text] [Related]
15. Metabolism and cytotoxicity of 5-azacytidine in cultured Novikoff rat hepatoma and P388 mouse leukemia cells and their enhancement by preincubation with pyrazofurin. Plagemann PG; Behrens M; Abraham D Cancer Res; 1978 Aug; 38(8):2458-66. PubMed ID: 78761 [TBL] [Abstract][Full Text] [Related]
16. Enzymatic assay for the antitumor agent-N-(phosphonacetyl)-L-aspartic acid (PALA). Friedman J; Moore EC; Hall SW; Loo TL Cancer Treat Rep; 1979 Jan; 63(1):85-8. PubMed ID: 421235 [TBL] [Abstract][Full Text] [Related]
17. Aspartate carbamoyltransferase activity, drug concentrations, and pyrimidine nucleotides in tissue from patients treated with N-(phosphonacetyl)-L-aspartate. Moore EC; Friedman J; Valdivieso M; Plunkett W; Marti JR; Russ J; Loo TL Biochem Pharmacol; 1982 Oct; 31(20):3317-21. PubMed ID: 7150358 [TBL] [Abstract][Full Text] [Related]
18. Pharmacological disposition of N-(phosphonacetyl)-L-aspartate in humans. Loo TL; Friedman J; Moore EC; Valdivieso M; Marti JR; Stewart D Cancer Res; 1980 Jan; 40(1):86-90. PubMed ID: 7349907 [TBL] [Abstract][Full Text] [Related]
19. Antitumor activity of the weekly intravenous push schedule of 5-fluoro-2'-deoxyuridine +/- N-phosphonacetyl-L-aspartate in mice bearing advanced colon carcinoma 26. van Laar JA; Durrani FA; Rustum YM Cancer Res; 1993 Apr; 53(7):1560-4. PubMed ID: 8453623 [TBL] [Abstract][Full Text] [Related]
20. Effect of N-phosphonacetyl-L-aspartate and D-glucosamine on the incorporation of 5-fluorouridine into normal tissues and an adenocarcinoma in the rat. Erichsen C; Christensson PI; Jakobsson B; Eriksson G; Yngner T; Jönsson PE; Stenram U Anticancer Res; 1987; 7(1):77-80. PubMed ID: 3566186 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]